Switch theme
Sign up to access all valuation multiples
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
2009
286
LTM Revenue $57.6M
LTM EBITDA -$212M
$228M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Nurix Therapeutics has a last 12-month revenue of $57.6M and a last 12-month EBITDA of -$212M.
In the most recent fiscal year, Nurix Therapeutics achieved revenue of $54.5M and an EBITDA of -$197M.
Nurix Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Nurix Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $77.0M | $54.5M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$141M | -$197M | XXX | XXX | XXX |
| EBITDA Margin | -184% | -360% | XXX | XXX | XXX |
| Net Profit | -$180M | -$144M | XXX | XXX | XXX |
| Net Margin | -234% | -264% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Nurix Therapeutics's stock price is $10.
Nurix Therapeutics has current market cap of $751M, and EV of $228M.
See Nurix Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $228M | $751M | XXX | XXX | XXX | XXX | $-2.94 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Nurix Therapeutics has market cap of $751M and EV of $228M.
Nurix Therapeutics's trades at 4.0x LTM EV/Revenue multiple, and -1.1x LTM EBITDA.
Analysts estimate Nurix Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Nurix Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $228M | XXX | XXX | XXX |
| EV/Revenue | 4.1x | XXX | XXX | XXX |
| EV/EBITDA | -1.1x | XXX | XXX | XXX |
| P/E | -3.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -1.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpNurix Therapeutics's NTM/LTM revenue growth is 11%
Nurix Therapeutics's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.9M for the same period.
Over next 12 months, Nurix Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Nurix Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Nurix Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -29% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -363% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 39% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -352% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.9M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 84% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 406% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 491% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nurix Therapeutics acquired XXX companies to date.
Last acquisition by Nurix Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Nurix Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Nurix Therapeutics founded? | Nurix Therapeutics was founded in 2009. |
| Where is Nurix Therapeutics headquartered? | Nurix Therapeutics is headquartered in United States of America. |
| How many employees does Nurix Therapeutics have? | As of today, Nurix Therapeutics has 286 employees. |
| Who is the CEO of Nurix Therapeutics? | Nurix Therapeutics's CEO is Dr. Arthur T. Sands, M.D.,PhD. |
| Is Nurix Therapeutics publicy listed? | Yes, Nurix Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Nurix Therapeutics? | Nurix Therapeutics trades under NRIX ticker. |
| When did Nurix Therapeutics go public? | Nurix Therapeutics went public in 2020. |
| Who are competitors of Nurix Therapeutics? | Similar companies to Nurix Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Nurix Therapeutics? | Nurix Therapeutics's current market cap is $751M |
| What is the current revenue of Nurix Therapeutics? | Nurix Therapeutics's last 12-month revenue is $57.6M. |
| What is the current EBITDA of Nurix Therapeutics? | Nurix Therapeutics's last 12-month EBITDA is -$212M. |
| What is the current EV/Revenue multiple of Nurix Therapeutics? | Current revenue multiple of Nurix Therapeutics is 4.0x. |
| What is the current EV/EBITDA multiple of Nurix Therapeutics? | Current EBITDA multiple of Nurix Therapeutics is -1.1x. |
| What is the current revenue growth of Nurix Therapeutics? | Nurix Therapeutics revenue growth between 2023 and 2024 was -29%. |
| Is Nurix Therapeutics profitable? | Yes, Nurix Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
